Viskase Holdings, Inc. (VISK): Operating Cash Flow
-$3.01M
Year ended 2025-12-31
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$3.01M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $1.12M | -14.0% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $1.30M | n/m | 2025-02-21, From 2023-01-01 |
| 2022-12-31 | -$659.0K | n/m | 2024-03-20, From 2022-01-01 |
| 2021-12-31 | -$501.0K | n/m | 2023-02-16, From 2021-01-01 |
| 2020-12-31 | -$380.0K | n/m | 2022-02-25, From 2020-01-01 |
| 2019-12-31 | $6.91M | n/m | 2021-02-23, From 2019-01-01 |
| 2018-12-31 | -$978.0K | n/m | 2020-02-19, From 2018-01-01 |
| 2017-12-31 | $6.47M | +149.0% | 2019-02-21, From 2017-01-01 |
| 2016-12-31 | $2.60M | n/a | 2018-03-21, From 2016-01-01 |
| No annual figure between 2012-12-31 and 2016-12-31. | |||
| 2012-12-31 | $8.45M | n/m | 2013-03-18, From 2012-01-01 |
| 2011-12-31 | -$12.72M | n/m | 2013-03-18, From 2011-01-01 |
| 2010-12-31 | $22.61M | +50.8% | 2013-03-18, From 2010-01-01 |
| 2009-12-31 | $15.00M | n/a | 2012-03-12, From 2009-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Viskase Holdings, Inc. (VISK) | 2025-12-31 | -$3.01M | n/m |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$56.96M | n/m |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | -$5.15M | n/m |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | -$24.59M | n/m |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | -$43.44M | n/m |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | -$77.16M | n/m |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | -$22.58M | n/m |
| IN8BIO, Inc. (INAB) | 2025-12-31 | -$12.71M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$97.21M | n/m |
Compare VISK, OCGN, PMCB, CGTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗